{"id":"W4230678902","doi":"10.1182/blood.v108.11.1998.1998","title":"Long Term Follow-Up of a Randomized Trial Comparing Response Adapted (RA), Non-Cross Resistant Induction and Consolidation with Idarubicin/Cytarabine (IDAC) Followed by Mitoxantone/Etoposide (NOVE) Compared with Consolidation with High Dose Cytarabine (HDAC) in Adult Patients with AML. A Study by the Canadian Leukemia Studies Group (CLSG).","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa; Quebec - Clinical Research Organization in Cancer; University of Saskatchewan; Saskatchewan Hospital; Dalhousie University; Ottawa Hospital","funders":"","keywords":"Idarubicin; Etoposide; Cytarabine; Internal medicine; Mitoxantrone; Medicine; Bilirubin; Gastroenterology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003705249,0.001571195,0.00293899,0.0003189532,0.0006612678,0.001329028,0.001114651,0.002192851,0.004513327],"category_scores_gemma":[0.003052822,0.0007504981,0.002958042,0.000463432,0.001524609,0.001336958,0.0005969757,0.004813892,0.0009877984],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001433911,"about_ca_system_score_gemma":0.00193044,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001958336,"about_ca_topic_score_gemma":0.003750103,"domain_scores_codex":[0.9982333,0.0009774492,0.0001295708,0.0002767789,0.0000848022,0.0002980168],"domain_scores_gemma":[0.9968257,0.0007639002,0.0006820344,0.0003387492,0.0001961631,0.001193373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9926167,0.00261383,0.0007130048,0.0000640885,0.0005367227,0.00001493704,0.00001924759,0.0001043184,0.0005097793,0.00002258084,0.0001508526,0.002633906],"study_design_scores_gemma":[0.8285949,0.1633252,0.005401851,0.00003100126,0.001164082,0.00003577485,0.00002375839,0.0003303252,0.0003886885,0.0001078245,0.0005810914,0.00001563161],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937216,0.002126531,0.0003191724,0.0005160992,0.000441754,0.001353098,0.0006175594,0.0000352513,0.000868944],"genre_scores_gemma":[0.9932153,0.0008305032,0.0004694924,0.0007407205,0.0005692597,0.001547828,0.0009845371,0.000009785168,0.001632484],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004513327,"threshold_uncertainty_score":0.01959544,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01367730642672829,"score_gpt":0.2657226953553863,"score_spread":0.252045388928658,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}